Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

The introduction of small molecule BRAF(V600) kinase inhibitors represents a milestone in the targeted therapy of patients with metastatic melanoma by a significant increase in therapeutic efficacy in terms of overall and progression-free survival compared with conventional chemotherapy. Beside BRAF(V600) inhibitor treatment, radiotherapy is a further mainstay for the therapy of metastatic melanoma and thus a concomitant or sequential application of BRAF(V600) inhibitors and radiotherapy is inevitable. Recent reports show a significant radiosensitization of the irradiated healthy tissue in patients with melanoma after the combination of radiotherapy and BRAF(V600) inhibitors, evoking concern in clinical practice. We review interactions of BRAF(V600) inhibitors and radiation with regard to antitumor effects and an increased radiotoxicity in the healthy tissue.


Sebastian Zahnreich, Arnulf Mayer, Carmen Loquai, Stephan Grabbe, Heinz Schmidberger. Radiotherapy with BRAF inhibitor therapy for melanoma: progress and possibilities. Future oncology (London, England). 2016 Jan;12(1):95-106

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 26616061

View Full Text